Submitted for Publication: February 4, 2013; final revision received April 30, 2013; accepted June 25, 2013.
Study concept and design: Schachern, Tsuprun, Juhn, Briles, Ferrieri.
Acquisition of data: Schachern, Tsuprun, Goetz, Cureoglu, Juhn, Ferrieri.
Analysis and interpretation of data: Schachern, Tsuprun, Cureoglu, Juhn, Briles, Paparella, Ferrieri.
Drafting of the manuscript: Schachern, Tsuprun, Goetz, Cureoglu, Briles.
Critical revision of the manuscript for important intellectual content: Schachern, Tsuprun, Cureoglu, Juhn, Briles, Paparella, Ferrieri.
Statistical analysis: Tsuprun, Briles.
Obtained funding: Juhn, Ferrieri.
Administrative, technical, or material support: Schachern, Tsuprun, Juhn, Briles, Ferrieri.
Study supervision: Cureoglu, Juhn, Briles, Paparella, Ferrieri.
Conflict of Interest Disclosures: Pneumococcal surface protein A has been patented for use in vaccines by The University of Alabama at Birmingham. Because Dr Briles is listed as an inventor on those patents, he may receive royalties if a PspA-containing vaccine is licensed. The laboratory of Dr Briles is or has been supported by the National Institutes of Health, Bill & Melinda Gates Foundation, PATH Foundation, Sanofi Pasteur, ConSino Vaccine, WCU, and private donations. Dr Briles is or has been a consultant and advisor to the PATH Foundation (uncompensated), Sanofi Pasteur (compensated), Merck (compensated), and the National Institutes of Health (compensated). Sanofi Pasteur, the PATH Foundation, and ConSino Vaccine are developing pneumococcal protein vaccines.
Funding/Support: This work was supported in part by National Institutes of Health grants R01 DC006452 and 3U24 DC011968-01 from the National Institute on Deafness and Other Communication Disorders and R01 A1021548 from the National Institute of Allergy and Infectious Diseases, as well as by the International Hearing Foundation, the Starkey Hearing Foundation, and 5M Lions International.
Previous Presentation: This work was presented at the 35th Annual Midwinter Meeting of the Association for Research in Otolaryngology; February 28, 2012; San Diego, California.
Additional Contributions: James C. Paton contributed the 2 mutants lacking Ply for use in these studies, Janice King and Pat Coan verified the identify of the serotype 2 strain D39 mutants, and Monika Schachern provided technical assistance.